HeartBeam, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by HeartBeam, Inc. (NASDAQ: BEAT) on October 17, 2024. The report details significant changes to the Company's executive leadership structure effective October 21, 2024. HeartBeam is an emerging growth company focused on developing vector-based technology for cardiovascular diagnostics, currently working toward FDA 510(k) clearance.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on executive appointments and employment terms.
Material Changes
- CEO Appointment: Robert Eno was appointed Chief Executive Officer, effective October 21, 2024. He previously served as President since January 2023.
- President Appointment: Branislav Vajdic, PhD, the Founder and former CEO, was appointed President, effective October 21, 2024.
- Compensation Terms: Mr. Eno's new employment agreement sets an annual base salary of $400,000, payable semi-monthly. He is eligible for an incentive bonus of up to 60% of his base salary based on corporate goals. A full review of equity ownership and long-term incentives is scheduled for 2025.
- Role Transition: Dr. Vajdic's compensation structure remains unchanged. His new role focuses on technology innovation, R&D, and AI applications, while Mr. Eno will lead commercialization and growth efforts.
Outlook, Risks, and Management Commentary
Management indicates this leadership transition is part of a long-planned strategy to align the Company's structure with its growth phase. Mr. Eno brings over 30 years of experience in go-to-market strategies for breakthrough medical products, including noninvasive FFRCT and laser cataract surgery. Dr. Vajdic will continue to drive the development of the Company's proprietary vector-based technology. The filing notes no related party transactions regarding these appointments.
Investor Verification Checklist
- Verify the effective date of the leadership transition (October 21, 2024) against internal corporate calendars.
- Review the full text of the CEO Employment Agreement (Exhibit 10.2) and President Employment Agreement (Exhibit 10.3) for detailed terms not summarized in the 8-K.
- Monitor the 2025 Compensation Committee review for details on the proposed long-term equity incentives for the CEO.
- Confirm the Company's progress toward FDA 510(k) clearance for its vector-based technology as the primary near-term operational milestone.